Wenqing Jiang

This inventor holds 8 USPTO granted patents and 14 published patent applications and 1 EPO patent. Top assignees: Abl Bio Inc., I-Mab Biopharma US Limited, Glaxosmithkline Intellectual Property Development Limited. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Wenqing Jiang. Retrieved from https://idiyas.com/inventor/wenqing-jiang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 8 (Patent Applications = 14)

% Patents Active = 75.0

EPO Patents = 1 (Patent Applications = 19)

Average Co-Inventor Count = 8.7

ph-index = 2

Forward Citations = 9(Granted Patents)

Company Filing History:

I-Mab Biopharma US Limited

patents

2 out of 242

Glaxosmithkline Intellectual Property Development Limited

I-Mab Biopharma (Hangzhou) Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2018-2026

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577313 - ANTI-CLAUDIN 18.2 AND ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF (2026-03-17),

2. 12195538 - Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof (2025-01-14),

3. 12173070 - Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof (2024-12-24),

4. 11414485 - Anti-LAG-3 antibodies and uses thereof (2022-08-16),

5. 11261259 - Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereof (2022-03-01),

6. 11078287 - Binding agonist for treatment of neurological and other disorders (2021-08-03),

7. 10577421 - Anti-LAG-3 antibodies and uses thereof (2020-03-03),

8. 9914781 - Binding agonist for treatment of neurological and other disorders (2018-03-13),

Title: Wenqing Jiang: Innovator in Bispecific Antibodies

Introduction

Wenqing Jiang is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of bispecific antibodies. With a total of 8 patents to his name, Jiang's work focuses on innovative therapeutic solutions for various diseases.

Latest Patents

Jiang's latest patents include groundbreaking inventions such as the "Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof." This patent describes a bispecific antibody that effectively blocks the interactions between PD-L1 and its receptor PD-1, as well as between 4-1BB and its ligand. The antibody is noted for its high binding affinity to both PD-L1 and 4-1BB proteins. Another significant patent is the "Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof." This invention also targets PD-L1, blocking its interaction with PD-1, and additionally inhibits the interaction between LAG3 and its ligand. The bispecific antibody demonstrates high binding affinity to both PD-L1 and LAG3 proteins, providing a promising avenue for therapeutic development.

Career Highlights

Throughout his career, Wenqing Jiang has worked with notable companies in the biopharmaceutical sector. He has been associated with Abl Bio Inc. and GlaxoSmithKline Intellectual Property Development Limited. His work in these organizations has contributed to advancements in antibody therapies and their applications in treating various medical conditions.

Collaborations

Jiang has collaborated with esteemed colleagues, including Lei Fang and Zhengyi Wang. These partnerships have fostered innovation and have been instrumental in the development of his patented technologies.

Conclusion

Wenqing Jiang stands out as a leading inventor in the field of bispecific antibodies, with a strong portfolio of patents that reflect his innovative spirit and dedication to advancing medical science. His contributions are paving the way for new therapeutic options in the treatment of diseases.

Profile summary based on public USPTO records.